Our work on CRISPR-Cas9 had two parts : on the one hand the work with stakeholders, in order to learn more on CRISPR-Cas9, and on the other hand the public engagement we made for popular science, through several activities.
+
=The societal issues of CRISPR/Cas9=
−
=Conference: the societal issues of CRISPR-Cas9=
+
Guided by curiosity we tried to establish a public dialogue beyond the lab on the societal issues of CRISPR/Cas9. We met public and stakeholders and tried to combine their contributions.
+
What we wanted was the ability for everyone to express an opinion on science. Everyone should be able to question Synthetic Biology, professional or simple citizen. This is even more true with CRISPR/Cas9. The ethical question behind is so big every citizen should be involved.
+
We tried to gather all of the opinion on the societal issues of CRISPR-Cas9, from different fields, but also from public and professionals.
−
[[File:Conference.jpg|200px|left|thumb| French poster of the conference on the societal issues of CRISPR-Cas9]]
+
Our concern about Public Engagement is so strong we made "Inclusiveness" as one of the principles of our Responsible Research and Innovation Test. To learn more about it, SEE HERE METTRE LIEN. When we asked to 17 teams to fill this test we saw how much inclusiveness is important among iGEM teams.
−
[[File:Conference2.jpg|200px|right]]
+
+
Firstly, we tried to have a great outreach, then we learned a lot on CRISPR/Cas9 by meeting politics, scientists or patent Attorneys. At last, we connected public and stakeholders during a conference on the societal issues of CRISPR/Cas9.
−
Because we had a strong concern both on popular science and meeting stakeholders, we hold a conference in our university, in front of students, with two researchers, Jean Denis Faure, a researcher and teacher at AgroParisTech school using CRISPR-Cas9 on plants, and Pierre Walrafen an European patent attorney. <br>
+
=Outreach=
−
We tried with our guests to think about the societal issues of CRISPR-Cas9, for the ethics, the law and the economy. The ethical problems CRISPR-Cas9 is bringing are huge, and for most of them, unknown. The ethical problems comes with what is done with the technology : therapeutical applications ex vivo or for genetical diseases, or applications on embryos and germ cells. The ethical problems comes along with the question of transhumanism. The issues are rising because of the simplicity of CRISPR-Cas9, authorizing a wider scientific audience to edit the genome. <br>
+
−
About the legal framework, our speakers made a comparison between the European legal framework, the process based evaluation, and the product based evaluation, and how the patentability was in Europe restrained by a principle of public order. To learn more about GMO regulation, [https://2016.igem.org/Team:Paris_Saclay/Human_Practices/GMO_Regulation click here].
+
−
=Synthetic Biology Survey=
+
==Synthetic Biology Survey==
In a first step, in order to build a better outreach, we wanted to know how much people knew about synthetic biology. We made a survey and spread it as much as possible.
In a first step, in order to build a better outreach, we wanted to know how much people knew about synthetic biology. We made a survey and spread it as much as possible.
Line 67:
Line 67:
The “Festival Vivant” is a three days festival, to debate and share views about living organisms and the way we use them. During these three days you could find conferences, workshops and meetings. The iGEM Paris Saclay’s team was there to present the field of synthetic biology and our iJ’AIME project. This festival presented different insights about living organisms to professionals, students and general audience. This festival gave us an other opportunity to do popular science. On this occasion we worked on popularising science : we modeled our project, and presented posters about it.
The “Festival Vivant” is a three days festival, to debate and share views about living organisms and the way we use them. During these three days you could find conferences, workshops and meetings. The iGEM Paris Saclay’s team was there to present the field of synthetic biology and our iJ’AIME project. This festival presented different insights about living organisms to professionals, students and general audience. This festival gave us an other opportunity to do popular science. On this occasion we worked on popularising science : we modeled our project, and presented posters about it.
−
=Exhibitions=
+
==Exhibitions==
The iGEM Paris Saclay 2016 team made an exhibition in Nanterre’s University, a french university that is mostly non-scientific. We made posters, explained to students what was synthetic biology. It was a successful exhibition because the discussion we had with students were very different from discussion from scientific or general audiences !
The iGEM Paris Saclay 2016 team made an exhibition in Nanterre’s University, a french university that is mostly non-scientific. We made posters, explained to students what was synthetic biology. It was a successful exhibition because the discussion we had with students were very different from discussion from scientific or general audiences !
−
=Vox Pop=
+
==Vox Pop==
Our team made a vox pop in a park in Paris, “Les jardins du Luxembourg”. We wanted to know if people ever heard of the field of synthetic biology, and if not spread the field and get their opinion on the subject.<br>
Our team made a vox pop in a park in Paris, “Les jardins du Luxembourg”. We wanted to know if people ever heard of the field of synthetic biology, and if not spread the field and get their opinion on the subject.<br>
What did we learn of this experiments ? Most of the people we met trust scientist to be responsible in their use, and doesn’t feel legitimate to bring a critic on a subject they don’t master. <br>
What did we learn of this experiments ? Most of the people we met trust scientist to be responsible in their use, and doesn’t feel legitimate to bring a critic on a subject they don’t master. <br>
+
+
+
+
=Meeting stakeholders=
=Meeting stakeholders=
Line 97:
Line 101:
Legally speaking, CRISPR does not raise any issue, patent law is the law of innovation. Research and legal protection can work together. The problem comes from a misguided perception: patentability provides a return on investment which allows then to fund future researches. The example is clear when it comes to fund research for rare diseases. In those cases, where public fund is difficult to obtain because the number of patients is small, patentability offers a solution.
Legally speaking, CRISPR does not raise any issue, patent law is the law of innovation. Research and legal protection can work together. The problem comes from a misguided perception: patentability provides a return on investment which allows then to fund future researches. The example is clear when it comes to fund research for rare diseases. In those cases, where public fund is difficult to obtain because the number of patients is small, patentability offers a solution.
Patent law is not there to restrain scientists in their work, indeed, 80% of the scientific information is contained in those patents. As a consequence, Patent law must be seen more as a source of economic development and a source of information.
Patent law is not there to restrain scientists in their work, indeed, 80% of the scientific information is contained in those patents. As a consequence, Patent law must be seen more as a source of economic development and a source of information.
−
In France, the tradition for scientist is to published their results for the recognition from their peers. This tradition destroys the requirement of novelty necessary to patent any invention. Thus, in France even if the country has the first place for innovation, there is a lack of valorization and protection.
+
In France, the tradition for scientist is to published their results for the recognition from their peers. This tradition destroys the requirement of novelty necessary to patent any invention. Thus, in France even if the country has the first place for innovation, there is a lack of valorization and protection
+
+
= Last step : connect public and stakeholders=
+
+
If we met public and stakeholders to improve our research on the societal issues of CRISPR/Cas9 we also connected the two. This connection happened during a conference we made about the societal issues of CRISPR/Cas9.
+
+
==Conference: the societal issues of CRISPR-Cas9==
+
+
[[File:Conference.jpg|200px|left|thumb| French poster of the conference on the societal issues of CRISPR-Cas9]]
+
[[File:Conference2.jpg|200px|right]]
+
+
+
Because we had a strong concern both on popular science and meeting stakeholders, we hold a conference in our university, in front of students, with two researchers, Jean Denis Faure, a researcher and teacher at AgroParisTech school using CRISPR-Cas9 on plants, and Pierre Walrafen an European patent attorney. <br>
+
We tried with our guests to think about the societal issues of CRISPR-Cas9, for the ethics, the law and the economy. The ethical problems CRISPR-Cas9 is bringing are huge, and for most of them, unknown. The ethical problems comes with what is done with the technology : therapeutical applications ex vivo or for genetical diseases, or applications on embryos and germ cells. The ethical problems comes along with the question of transhumanism. The issues are rising because of the simplicity of CRISPR-Cas9, authorizing a wider scientific audience to edit the genome. <br>
+
About the legal framework, our speakers made a comparison between the European legal framework, the process based evaluation, and the product based evaluation, and how the patentability was in Europe restrained by a principle of public order. To learn more about GMO regulation, [https://2016.igem.org/Team:Paris_Saclay/Human_Practices/GMO_Regulation click here].